They are well run. Paul Hopper is on the board - former Chairman of Viralytics (acquired in June 2018 by Merck for $500m), Founder & Director of Prescient, Founder of Imugene & Polynoma LLC. He has a pretty reasonable track record.
MKT The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint
